Pages that link to "Q34405452"

The following pages link to AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. (Q34405452):

Displaying 50 items.

• MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein function (Q24540167) (← links)
• Epigenetics of cervical cancer. An overview and therapeutic perspectives (Q24812104) (← links)
• Targeted Cancer Therapy: Vital Oncogenes and a New Molecular Genetic Paradigm for Cancer Initiation Progression and Treatment (Q28076462) (← links)
• AML1 interconnected pathways of leukemogenesis (Q28184349) (← links)
• A novel application of furazolidone: anti-leukemic activity in acute myeloid leukemia (Q28535230) (← links)
• ETO/MTG8 is an inhibitor of C/EBPbeta activity and a regulator of early adipogenesis (Q28588161) (← links)
• AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia (Q28751687) (← links)
• Novel RNA-binding properties of the MTG chromatin regulatory proteins (Q33379264) (← links)
• Mutations of Chromatin Structure Regulating Genes in Human Malignancies (Q33600399) (← links)
• Point mutation in AML1 disrupts subnuclear targeting, prevents myeloid differentiation, and effects a transformation-like phenotype. (Q33821606) (← links)
• The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice (Q33895709) (← links)
• The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes. (Q33995514) (← links)
• The hematopoietic transcription factor AML1 (RUNX1) is negatively regulated by the cell cycle protein cyclin D3. (Q34150889) (← links)
• Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK network (Q34372000) (← links)
• Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts (Q34578418) (← links)
• Histone-deacetylase inhibitors: novel drugs for the treatment of cancer (Q34743301) (← links)
• The acute myeloid leukemia fusion protein AML1-ETO targets E proteins via a paired amphipathic helix-like TBP-associated factor homology domain (Q34771988) (← links)
• The promiscuous MLL gene links chromosomal translocations to cellular differentiation and tumour tropism (Q34838272) (← links)
• Lymphoma- and leukemia-associated chromosomal translocations in healthy individuals (Q35056472) (← links)
• The core-binding factor leukemias: lessons learned from murine models (Q35062441) (← links)
• Retinoids in cancer therapy and chemoprevention: promise meets resistance (Q35567239) (← links)
• Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo (Q35751083) (← links)
• Molecular therapeutic approaches to acute myeloid leukemia: targeting aberrant chromatin dynamics and signal transduction. (Q35782919) (← links)
• The MTG proteins: chromatin repression players with a passion for networking (Q35808823) (← links)
• The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO. (Q35828623) (← links)
• Cell type dependent regulation of multidrug resistance-1 gene expression by AML1-ETO. (Q36102812) (← links)
• Predicting the effect of transcription therapy in hematologic malignancies (Q36109663) (← links)
• Acute promyelocytic leukemia: a model of molecular target based therapy. (Q36270144) (← links)
• AML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency (Q36371457) (← links)
• p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death (Q36445874) (← links)
• An experimentally validated network of nine haematopoietic transcription factors reveals mechanisms of cell state stability. (Q36703674) (← links)
• Whole genome scanning as a cytogenetic tool in hematologic malignancies (Q36835203) (← links)
• From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: leukemia research in the genomic era. (Q36920786) (← links)
• CEH-20/Pbx and UNC-62/Meis function upstream of rnt-1/Runx to regulate asymmetric divisions of the C. elegans stem-like seam cells (Q37011419) (← links)
• MLL5 contributes to hematopoietic stem cell fitness and homeostasis (Q37100715) (← links)
• Functional integration of microRNAs into oncogenic and tumor suppressor pathways (Q37125039) (← links)
• BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia (Q37434990) (← links)
• Core binding factor at the crossroads: determining the fate of the HSC. (Q37610919) (← links)
• AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches (Q38033116) (← links)
• Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders (Q38240733) (← links)
• Human CD34+ cells expressing the inv(16) fusion protein exhibit a myelomonocytic phenotype with greatly enhanced proliferative ability (Q38288838) (← links)
• The multi-functional cellular adhesion molecule CD44 is regulated by the 8;21 chromosomal translocation (Q38299682) (← links)
• Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. (Q38343552) (← links)
• Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes (Q38710509) (← links)
• VENTX induces expansion of primitive erythroid cells and contributes to the development of acute myeloid leukemia in mice (Q38728879) (← links)
• Silencing AML1-ETO gene expression leads to simultaneous activation of both pro-apoptotic and proliferation signaling. (Q39004686) (← links)
• AML1/ETO sensitizes via TRAIL acute myeloid leukemia cells to the pro-apoptotic effects of hypoxia (Q39181108) (← links)
• Covalent Modifications of RUNX Proteins: Structure Affects Function (Q39181397) (← links)
• AML1-ETO targets and suppresses cathepsin G, a serine protease, which is able to degrade AML1-ETO in t(8;21) acute myeloid leukemia (Q39340944) (← links)
• Multivalent binding of the ETO corepressor to E proteins facilitates dual repression controls targeting chromatin and the basal transcription machinery. (Q39872185) (← links)